NCT06632379View on ClinicalTrials.gov

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

PHASE4RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 3, 2025

Primary Completion Date

September 15, 2026

Study Completion Date

December 15, 2026

Conditions
Hypertensive Disorders of PregnancyPreeclampsiaGestational Hypertension
Interventions
DRUG

Atorvastatin 10 mg

Participants will be assigned to 10 mg Atorvastatin

DRUG

Placebo

Participants will be assigned to identical appearing placebo

Trial Locations (1)

43210

RECRUITING

The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER